Skip Navigation



Human Molecular Genetics Advance Access published online on September 2, 2008

Human Molecular Genetics, doi:10.1093/hmg/ddn266
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
17/23/3708    most recent
ddn266v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hiruma, Y.
Right arrow Articles by Windle, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hiruma, Y.
Right arrow Articles by Windle, J. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment

Yuko Hiruma1, Noriyoshi Kurihara1, Mark A. Subler2, Hua Zhou3, Christina S. Boykin2, Heju Zhang4, Seiichi Ishizuka5, David W. Dempster3,6, G. David Roodman1,7 and Jolene J. Windle2,4,*

1 Department of Medicine/Hem-Onc, University of Pittsburgh Medical Center, Pittsburgh, PA 15240, USA 2 Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, USA 3 Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA 4 Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA 5 Teijin Bio-Medical Research, Tokyo 191-8512, Japan 6 Department of Pathology, Columbia University, College of Physician and Surgeons, New York, NY 10032, USA 7 Department of Medicine/Hem-Onc, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA

* To whom correspondence should be addressed at: Department of Human and Molecular Genetics, Virginia Commonwealth University, P.O. Box 980033, Richmond, VA 23298-0033, USA; Tel: 804-828-5843; Fax: 804-828-5836; E-mail: jjwindle{at}vcu.edu

Received July 8, 2008; Revised August 22, 2008; Accepted August 22, 2008

Paget's disease of bone (PDB) is the second most common bone disease and is characterized by focal bone lesions which contain large numbers of abnormal osteoclasts and very active normal osteoblasts in a highly osteoclastogenic marrow microenvironment. The etiology of PDB is not well understood and both environmental and genetic causes have been implicated in its pathogenesis. Mutations in the SQSTM1/p62 gene have been identified in up to 30% of Paget's patients. To determine if p62 mutation is sufficient to induce PDB, we generated mice harboring a mutation causing a P-to-L substitution at residue 394 (the murine equivalent of human p62P392L, the most common PDB-associated mutation). Bone marrow cultures from p62P394L mice formed increased numbers of osteoclasts in response to RANKL, TNF-{alpha} or 1{alpha},25-(OH)2D3, similar to PDB patients. However, purified p62P394L osteoclast precursors depleted of stromal cells were no longer hyper-responsive to 1{alpha},25-(OH)2D3, suggesting effects of the p62P394L mutation on the marrow microenvironment in addition to direct effects on osteoclasts. Co-cultures of purified p62P394L stromal cells with either wild-type or p62P394L osteoclast precursors formed more osteoclasts than co-cultures containing wild-type stromal cells due to increased RANKL production by the mutant stromal cells. However, despite the enhanced osteoclastogenic potential of both osteoclast precursors and marrow stromal cells, the p62P394L mice had histologically normal bones. These results indicate that this PDB-associated p62 mutation is not sufficient to induce PDB and suggest that additional factors acting together with p62 mutation are necessary for the development of PDB in vivo.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
E. Chamoux, J. Couture, M. Bisson, J. Morissette, J. P. Brown, and S. Roux
The p62 P392L Mutation Linked to Paget's Disease Induces Activation of Human Osteoclasts
Mol. Endocrinol., October 1, 2009; 23(10): 1668 - 1680.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Hiruma, T. Honjo, D. F. Jelinek, J. J. Windle, J. Shin, G. D. Roodman, and N. Kurihara
Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation
Blood, May 14, 2009; 113(20): 4894 - 4902.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.